Clinical trials: sponsored by Zhejiang Cancer Hospital
Thyroid Nodule, Thyroid Cancer
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
The purpose of this study is to evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nodules with suspecious ultrasound features
- Trial name
- NCT05025046
- Testing
- Thyroscan
- Where
- 4 sites in China
- Volunteers
- 250 people
- Sponsor
- Rigen Biotech
Advanced Gastric or Gastroesophageal Junction Cancer
A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
The objective of the study is to evaluate Tolerability, Safety, and primary Efficacy of Gentuximab Injection at different dosage in combination with Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer patients, to…
- Trial name
- NCT04053205
- Testing
- Gentuximab, Paclitaxel
- Where
- 12 sites in China
- Volunteers
- 76 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Solid Tumors
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors
Brief Summary: This is a Phase I, first-in-human, open-label, multi-center study designed to explore the safety, tolerability, PK, and anti-tumor antitumor activity of ANS014004 monotherapy in subjects with locally advanced or…
- Trial name
- NCT06328439
- Testing
- ANS014004
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Solid Tumor Malignancies
A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors
The goal of this phase I, first-in-human, open-label study is to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SWA1211 in subjects with advanced solid tumors.
- Trial name
- NCT07363967
- Testing
- SWA1211
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing StoneWise Technology Co., Ltd
Advanced Solid Tumor
TIL for Patients With Advanced Solid Tumor
Background: Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to patients.
- Trial name
- NCT06334783
- Testing
- Autologous tumor-infiltrating lymphocyte cells
- Where
- 3 sites in China
- Volunteers
- 5 people
- Sponsor
- Hervor Therapeutics
Solid Tumors
A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors
- Trial name
- NCT06992687
- Testing
- HB0052 Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-center, single-arm, open-label, Phase II clinical trial which explores the safety and efficacy of TGRX-326 in patients with ALK-positive advanced NSCLC who have failed prior 2nd-generation ALK treatments due to…
- Trial name
- NCT05955391
- Testing
- TGRX-326
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Chronic Myeloid Leukemia, Accelerated Phase CML
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI)…
- Trial name
- NCT06453902
- Testing
- TGRX-678
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Cancer, Neoplasms
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
- Conditions
- Cancer, Neoplasms, Neoplasms, Breast, Tumor
- Trial name
- NCT06819215
- Testing
- VB15010
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Colorectal Cancer, Colorectal Adenoma
Integrated Chinese and Western Medicine Specialized Disease Cohort for Colorectal Cancer
This is a nationwide cohort study on integrated traditional Chinese and Western medicine for colorectal cancer. The aim is to elucidate the distribution patterns of TCM syndromes in colorectal cancer and colorectal adenoma…
- Trial name
- NCT06136026
- Volunteers
- 50,000 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Breast Cancer, Ovarian Cancer
Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients
Bioequivalence study is proposed to be carried out on patients of breast cancer/ ovarian cancer, who are administrated for Doxorubicin Hydrochloride Liposomal Injection Lipodox® or Caelyx® in a dose of 50 mg/m2.
- Trial name
- NCT05273944
- Testing
- Doxorubicin Hydrochloride Liposome Injection
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients
The purpose of this trail is to evaluate the performance of Genetron lung cancer panel in non-small cell lung cancer patients using semiconductor sequencing method.
- Trial name
- NCT05023746
- Testing
- Genetron lung cancer panel
- Where
- 4 sites in China
- Volunteers
- 1,052 people
- Sponsor
- Genetron Health
Neutropenia
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
This was a randomized, open-label, active-controlled, dose-finding, phase II study to evaluate the efficacy and safety of 2 doses of F-627 compared to Filgrastim in women with breast cancer receiving myelotoxic chemotherapy.
- Trial name
- NCT02521441
- Testing
- F-627, Filgrastim
- Where
- China
- Volunteers
- 138 people
- Sponsor
- EVIVE Biotechnology
Neutropenia
Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
This study will assess the Efficacy and Safety of different doses of PEG-rhG-CSF and a single-dose of G-CSF in Preventing Chemotherapy-induced Neutropenia.
- Trial name
- PEG-rhG-CSF (NCT01918241)
- Testing
- pegfilgrastim,30mcg/kg, pegfilgrastim, 60mcg/kg, pegfilgrastim, 100mcg/kg
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Non-small Cell Lung Cancer
Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to access the effect and safety of radiotherapy combined whth Iressa for patients with locally advanced non-small cell lung cancer with harboring active EGFR mutations.
- Trial name
- NCT01391260
- Testing
- Gefitinib
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- ZhuGuangYing